Showing articles whose micro-themes are very close to:
#Maftivimab prioritization
- No closely related articles found yet.
- WHO Advisory Group Recommends Maftivimab for Clinical Trials in Bundibugyo Ebola Outbreak (rttnews.com) | 11d ago
- WHO Technical Advisory Group recommends BDBV-specific vaccines as preferred, considers Ervebo for post-exposure use in Bundibugyo outbreak (iris.who.int) | 15d ago
- Overview of experimental vaccines and treatments for Bundibugyo Ebola in DRC outbreak (cnbcafrica.com) | 11d ago
- WHO Technical Advisory Group Prioritizes Vaccine Candidates for Bundibugyo Virus Disease in DRC and Uganda (who.int) | 12d ago
- Updated WHO list of emerging pathogens includes Ebola for future outbreak preparedness (pmc.ncbi.nlm.nih.gov) | 15d ago
- Brief review of Ebola virus disease and the One Health approach (pmc.ncbi.nlm.nih.gov) | 15d ago
- WHO reports 906 suspected Ebola cases and 223 deaths from Bundibugyo strain in DRC (indiatoday.in) | 11d ago
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114 (pmc.ncbi.nlm.nih.gov) | 17d ago
- Regeneron Secures $125M for Antibody-Helicon Conjugates; EMA Accepts Otarmeni MAA; Maftivimab Shows Lab Activity Against Bundibugyo Ebolavirus (tradingview.com) | 17d ago
- WHO selects maftivimab, remdesivir, and MBP134 as priority Ebola drugs for trials (pharmaphorum.com) | 11d ago
- WHO prioritizes Regeneron's maftivimab for Bundibugyo ebolavirus trials (simplywall.st) | 9d ago
- FDA approves Ebanga (ansuvimab-zykl) for Zaire ebolavirus treatment (fda.gov) | 14d ago
- WHO Issues Updated Guideline on Therapeutics for Ebola Virus Disease (iris.who.int) | 14d ago
Showing page 1 of 1
(13 total results)
← Prev
Next →